Completed

Stem Cell Augmented, Elutriated Grafts for Allogeneic Bone Marrow Transplantation

What is being tested

graft versus host disease prophylaxis/therapy

+ allogeneic bone marrow transplantation

BiologicalProcedure

Who is being recruted

Lymphadenopathy+109

+ Urogenital Diseases

+ Genital Diseases

Until 65 Years

See all eligibility criteria

How is the trial designed

Supportive Care Study

Interventional

Study Start: March 1997

See protocol details

Summary

Principal SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Last updated: May 2, 2014

Sourced from a government-validated database.Claim as a partner

Study start date: March 1, 1997

Actual date on which the first participant was enrolled.

OBJECTIVES: Determine whether stem cell augmented, elutriated grafts prevent graft versus host disease in patients undergoing allogeneic bone marrow transplantation. OUTLINE: Patients receive elutriated CD34+ augmented donor bone marrow on day 0. Bone marrow samples are obtained before day 100, around 6 months, and 1 year after transplant. PROJECTED ACCRUAL: Not specified

NCT00003538

Principal SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Last updated: May 2, 2014

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Supportive Care Study

These studies explore ways to improve comfort and daily life for people living with a condition. They may focus on easing symptoms, reducing treatment side effects, or supporting overall well-being.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Until 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

LymphadenopathyUrogenital DiseasesGenital DiseasesAdnexal DiseasesBlood Protein DisordersBone Marrow DiseasesBreast DiseasesCarcinomaCardiovascular DiseasesCell Transformation, NeoplasticChronic DiseaseDNA Virus InfectionsEndocrine System DiseasesEndocrine Gland NeoplasmsFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleGenital Diseases, MaleGenital Neoplasms, FemaleGenital Neoplasms, MaleGonadal DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersHerpesviridae InfectionsImmune System DiseasesImmunoproliferative DisordersInfectionsKidney DiseasesKidney NeoplasmsLeukemiaLeukemia, LymphoidLeukemia, MyeloidLymphatic DiseasesLymphomaLymphoproliferative DisordersMyeloproliferative DisordersCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Germ Cell and EmbryonalNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueNeoplastic ProcessesNeoplastic Syndromes, HereditaryOvarian DiseasesOvarian NeoplasmsParaproteinemiasPathologic ProcessesSkin DiseasesPathological Conditions, Signs and SymptomsTesticular DiseasesTumor Virus InfectionsUrogenital NeoplasmsUrologic DiseasesUrologic NeoplasmsVascular DiseasesVirus DiseasesLeukemia, B-CellHistiocytosisHistiocytic Disorders, MalignantLymphoma, B-CellLymphoma, T-CellSkin and Connective Tissue DiseasesNeuroectodermal TumorsNeoplasms, Complex and MixedNeuroectodermal Tumors, Primitive, PeripheralNeuroectodermal Tumors, PrimitiveNeoplasms, NeuroepithelialEpstein-Barr Virus InfectionsHemostatic DisordersDisease AttributesGenetic Diseases, InbornFemale Urogenital DiseasesMale Urogenital DiseasesNeoplasms, Plasma CellMyelodysplastic-Myeloproliferative DiseasesCarcinogenesisCarcinoma, Ovarian EpithelialAnemiaBlast CrisisBreast NeoplasmsBurkitt LymphomaGraft vs Host DiseaseHodgkin DiseaseImmunoblastic LymphadenopathyLeukemia, Hairy CellLymphoma, FollicularLymphoma, Non-HodgkinWaldenstrom MacroglobulinemiaMultiple MyelomaMyelodysplastic SyndromesNeoplasmsWilms TumorNeuroblastomaRecurrenceTesticular NeoplasmsLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Biphenotypic, AcuteLeukemia, ProlymphocyticLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Accelerated PhaseLeukemia, Myeloid, Chronic-PhaseLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicLymphoma, Large-Cell, ImmunoblasticLymphoma, Large B-Cell, DiffuseLymphoma, Large-Cell, AnaplasticLymphoma, B-Cell, Marginal ZoneLymphoma, Mantle-CellPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaDendritic Cell Sarcoma, Interdigitating

Criteria

DISEASE CHARACTERISTICS: Histologically confirmed diagnosis of one the following: Acute myelogenous leukemia in CR1, ER1, CR2, ER2, CR3 Acute lymphocytic leukemia in CR1, ER1, CR2, ER2, CR3 Non-Hodgkin's lymphoma Hodgkin's lymphoma Multiple myeloma with no more than 12 months of prior alkylator based chemotherapy Myelodysplastic syndrome (MDS) Acute leukemia arising out of MDS Primary resistant acute leukemia Chronic myelomonocytic leukemia Aplastic anemia (40 years of age and over) Solid tumor malignancy (germ cell, sarcoma, breast, etc.) Genetic disorders or inborn errors of metabolism as defined by preparative regimen protocol Chronic myelogenous leukemia Must meet all inclusion criteria specified by the respective preparative regimen protocol No aplastic anemia under 40 years of age or myelofibrosis PATIENT CHARACTERISTICS: Age: 0.5 to 65 Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified PRIOR CONCURRENT THERAPY: Biologic therapy: No prior red blood cell or platelet transfusions from a sibling donor Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, United StatesOpen Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Google Maps

CompletedOne Study Center